Aptorum Group Limited (APM)
NASDAQ: APM · Real-Time Price · USD
1.030
+0.192 (22.90%)
At close: May 29, 2026, 4:00 PM EDT
0.9894
-0.0410 (-3.94%)
After-hours: May 29, 2026, 7:57 PM EDT
Aptorum Group Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
8.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 431.38K | -864.51K | -66.71% |
| Dec 31, 2022 | 1.30M | -245.89K | -15.95% |
| Dec 31, 2021 | 1.54M | 630.27K | 69.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.19M |
| BioAtla | 2.00M |
| Evogene | 1.84M |
| GeoVax Labs | 852.28K |
| Can-Fite BioPharma | 405.00K |
| Addex Therapeutics | 218.17K |
| AIM ImmunoTech | 94.00K |
| Silo Pharma | 72.10K |
APM News
- 2 months ago - Aptorum Group, DiamiR announce publication of microRNA biomarker study - TheFly
- 2 months ago - Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania - GlobeNewsWire
- 3 months ago - Aptorum Group receives noncompliance notification from Nasdaq - TheFly
- 4 months ago - Aptorum Group announces collab between DiamiR, Instant NanoBiosensors - TheFly
- 4 months ago - Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB's Automated APOE Testing Platform for Alzheimer's Disease - GlobeNewsWire
- 4 months ago - Aptorum Group files $75M mixed securities shelf - TheFly
- 6 months ago - DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference - GlobeNewsWire
- 6 months ago - Aptorum Group files to sell 2.06M Class A ordinary shares for holders - TheFly